Actively Recruiting

Phase Not Applicable
Age: 18Years +
All Genders
NCT07130773

Comparative Intra-procedural Evaluation of Farapulse and FARAWAVE Nav Catheters

Led by Cardiocentro Ticino · Updated on 2026-03-19

58

Participants Needed

1

Research Sites

55 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

The FARAPULSE PFA catheter (Boston Scientific), a first-generation Pulsed Field Ablation (PFA) tool, has demonstrated good performance in isolating pulmonary veins (PV). Several centers, including ours, utilize pre-procedural computer tomography (CT) to evaluate individual pulmonary vein anatomy and optimize ablation planning. However, these imaging modalities are costly. Additionally, CT imaging exposes patients to radiation, and introduce significant logistical challenges to the procedural workflow. The FARAWAVE Nav PFA catheter, a second-generation device, integrates magnetic navigation capabilities with detailed mapping and PFA therapy into a single tool. This system leverages the FARAVIEW Software Module, offering tailored mapping solutions visualized on the FARAPULSE PFA system, including the creation of voltage and activation maps. These features address the limitations of the first-generation FARAPULSE catheter and have the potential to improve procedural accuracy and the durability of pulmonary vein isolation. Moreover, they may obviate the need for pre-procedural CT, thereby reducing costs and minimizing patient radiation exposure. Our study evaluates whether the FARAWAVE Nav catheter, used without pre-ablation CT, allows for a reduction in fluoroscopy time and overall patient radiation exposure compared to the conventional workflow with the FARAPULSE catheter. Furthermore, we will assess procedural time, costs, number of PFA applications, and AF recurrence-free survival

CONDITIONS

Official Title

Comparative Intra-procedural Evaluation of Farapulse and FARAWAVE Nav Catheters

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Diagnosed atrial fibrillation (AF) confirmed by ECG, Holter monitor, or implantable cardiac device
  • Candidate for ablation according to current atrial fibrillation guidelines
  • Age 18 years or older at time of informed consent
  • Signed informed consent obtained
Not Eligible

You will not qualify if you...

  • Previous left atrial ablation or left atrial surgery
  • Presence of intracardiac thrombus
  • Persistent atrial fibrillation lasting more than 3 years
  • Severe mitral regurgitation or moderate-to-severe mitral stenosis
  • Pregnancy (all women under 50 years undergo an HCG blood test to exclude pregnancy)

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Cardiocentro Ticino - Ente Ospedaliero Cantonale

Lugano, Canton Ticino, Switzerland, 6900

Actively Recruiting

Loading map...

Research Team

M

Marco Bergonti, MD PhD

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here